BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Krammer F, Palese P. Universal Influenza Virus Vaccines That Target the Conserved Hemagglutinin Stalk and Conserved Sites in the Head Domain. J Infect Dis 2019;219:S62-7. [PMID: 30715353 DOI: 10.1093/infdis/jiy711] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 25.0] [Reference Citation Analysis]
Number Citing Articles
1 Subbbiah J, Oh J, Kim KH, Shin CH, Park BR, Bhatnagar N, Jung YJ, Lee Y, Wang BZ, Seong BL, Kang SM. Thermostable H1 hemagglutinin stem with M2e epitopes provides broad cross-protection against group1 and 2 influenza A viruses. Mol Ther Methods Clin Dev 2022;26:38-51. [PMID: 35755946 DOI: 10.1016/j.omtm.2022.05.007] [Reference Citation Analysis]
2 Varghese PM, Kishore U, Rajkumari R. Innate and adaptive immune responses against Influenza A Virus: Immune evasion and vaccination strategies. Immunobiology 2022. [DOI: 10.1016/j.imbio.2022.152279] [Reference Citation Analysis]
3 Park J, Fong Legaspi SL, Schwartzman LM, Gygli SM, Sheng Z, Freeman AD, Matthews LM, Xiao Y, Ramuta MD, Batchenkova NA, Qi L, Rosas LA, Williams SL, Scherler K, Gouzoulis M, Bellayr I, Morens DM, Walters K, Memoli MJ, Kash JC, Taubenberger JK. An inactivated multivalent influenza A virus vaccine is broadly protective in mice and ferrets. Sci Transl Med 2022;14:eabo2167. [DOI: 10.1126/scitranslmed.abo2167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Choy RKM, Bourgeois AL, Ockenhouse CF, Walker RI, Sheets RL, Flores J. Controlled Human Infection Models To Accelerate Vaccine Development. Clin Microbiol Rev. [DOI: 10.1128/cmr.00008-21] [Reference Citation Analysis]
5 Qiao Y, Zhang Y, Chen J, Jin S, Shan Y. A biepitope, adjuvant-free, self-assembled influenza nanovaccine provides cross-protection against H3N2 and H1N1 viruses in mice. Nano Res . [DOI: 10.1007/s12274-022-4482-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Subbiah J, Oh J, Kim KH, Shin CH, Park BR, Bhatnagar N, Seong BL, Wang BZ, Kang SM. A chimeric thermostable M2e and H3 stalk-based universal influenza A virus vaccine. NPJ Vaccines 2022;7:68. [PMID: 35768475 DOI: 10.1038/s41541-022-00498-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Li L, Changrob S, Fu Y, Stovicek O, Guthmiller JJ, McGrath JJC, Dugan HL, Stamper CT, Zheng NY, Huang M, Wilson PC. Librator: a platform for the optimized analysis, design, and expression of mutable influenza viral antigens. Brief Bioinform 2022:bbac028. [PMID: 35183062 DOI: 10.1093/bib/bbac028] [Reference Citation Analysis]
8 Dong C, Wang B. Engineered Nanoparticulate Vaccines to Combat Recurring and Pandemic Influenza Threats. Advanced NanoBiomed Research 2022;2:2100122. [DOI: 10.1002/anbr.202100122] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Moore KA, Ostrowsky JT, Kraigsley AM, Mehr AJ, Bresee JS, Friede MH, Gellin BG, Golding JP, Hart PJ, Moen A, Weller CL, Osterholm MT; Influenza Vaccines R&D Roadmap Taskforce. A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future. Vaccine 2021;39:6573-84. [PMID: 34602302 DOI: 10.1016/j.vaccine.2021.08.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
10 Kotey EN, Ampofo WK, Daines R, Sadeyen JR, Iqbal M, Quaye O. Immune Response in Mice Immunized with Chimeric H1 Antigens. Vaccines (Basel) 2021;9:1182. [PMID: 34696290 DOI: 10.3390/vaccines9101182] [Reference Citation Analysis]
11 Chen J, Wang J, Zhang J, Ly H. Advances in Development and Application of Influenza Vaccines. Front Immunol 2021;12:711997. [PMID: 34326849 DOI: 10.3389/fimmu.2021.711997] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
12 Narkhede YB, Gonzalez KJ, Strauch EM. Targeting Viral Surface Proteins through Structure-Based Design. Viruses 2021;13:1320. [PMID: 34372526 DOI: 10.3390/v13071320] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Paramsothy A, Lartey Jalloh S, Davies RA, Guttormsen AB, Cox RJ, Mohn KG. Humoral and cellular immune responses in critically ill influenza A/H1N1-infected patients. Scand J Immunol 2021;94:e13045. [PMID: 33891354 DOI: 10.1111/sji.13045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Sekiya T, Ohno M, Nomura N, Handabile C, Shingai M, Jackson DC, Brown LE, Kida H. Selecting and Using the Appropriate Influenza Vaccine for Each Individual. Viruses 2021;13:971. [PMID: 34073843 DOI: 10.3390/v13060971] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
15 Nguyen QT, Choi YK. Targeting Antigens for Universal Influenza Vaccine Development. Viruses 2021;13:973. [PMID: 34073996 DOI: 10.3390/v13060973] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
16 Sandor AM, Sturdivant MS, Ting JPY. Influenza Virus and SARS-CoV-2 Vaccines. J Immunol 2021;206:2509-20. [PMID: 34021048 DOI: 10.4049/jimmunol.2001287] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
17 Harrington WN, Kackos CM, Webby RJ. The evolution and future of influenza pandemic preparedness. Exp Mol Med 2021;53:737-49. [PMID: 33953324 DOI: 10.1038/s12276-021-00603-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 25.0] [Reference Citation Analysis]
18 Li L, Stovicek O, Guthmiller JJ, Changrob S, Fu Y, Dugan HL, Stamper CT, Zheng N, Huang M, Wilson PC. Librator, a platform for optimized sequence editing, design, and expression of influenza virus proteins.. [DOI: 10.1101/2021.04.29.441999] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Creanga A, Gillespie RA, Fisher BE, Andrews SF, Lederhofer J, Yap C, Hatch L, Stephens T, Tsybovsky Y, Crank MC, Ledgerwood JE, McDermott AB, Mascola JR, Graham BS, Kanekiyo M. A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies. Nat Commun 2021;12:1722. [PMID: 33741916 DOI: 10.1038/s41467-021-21954-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 17.0] [Reference Citation Analysis]
20 Tung Yep A, Takeuchi Y, Engelhardt OG, Hufton SE. Broad Reactivity Single Domain Antibodies against Influenza Virus and Their Applications to Vaccine Potency Testing and Immunotherapy. Biomolecules 2021;11:407. [PMID: 33802072 DOI: 10.3390/biom11030407] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Yan L, Sun L, Guo C, Li L, Sun J, Huang X, Zhao P, Xie X, Hu J. Neutralizing antibody PR8-23 targets the footprint of the sialoglycan receptor binding site of H1N1 hemagglutinin. J Med Virol 2021;93:3508-15. [PMID: 33410516 DOI: 10.1002/jmv.26779] [Reference Citation Analysis]
22 Park BR, Kim KH, Kotomina T, Kim MC, Kwon YM, Jeeva S, Jung YJ, Bhatnagar N, Isakova-Sivak I, Mezhenskaya D, Rudenko L, Wang BZ, Kang SM. Broad cross protection by recombinant live attenuated influenza H3N2 seasonal virus expressing conserved M2 extracellular domain in a chimeric hemagglutinin. Sci Rep 2021;11:4151. [PMID: 33603072 DOI: 10.1038/s41598-021-83704-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
23 Roubidoux EK, Carreño JM, McMahon M, Jiang K, van Bakel H, Wilson P, Krammer F. Mutations in the Hemagglutinin Stalk Domain Do Not Permit Escape from a Protective, Stalk-Based Vaccine-Induced Immune Response in the Mouse Model. mBio 2021;12:e03617-20. [PMID: 33593972 DOI: 10.1128/mBio.03617-20] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
24 Sangesland M, Lingwood D. Antibody Focusing to Conserved Sites of Vulnerability: The Immunological Pathways for 'Universal' Influenza Vaccines. Vaccines (Basel) 2021;9:125. [PMID: 33562627 DOI: 10.3390/vaccines9020125] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
25 Dhakal S, Deshpande S, McMahon M, Strohmeier S, Krammer F, Klein SL. Female-biased effects of aging on a chimeric hemagglutinin stalk-based universal influenza virus vaccine in mice. Vaccine 2020:S0264-410X(20)31510-3. [PMID: 33293159 DOI: 10.1016/j.vaccine.2020.11.057] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
26 Kwong PD, DeKosky BJ, Ulmer JB. Antibody-guided structure-based vaccines. Semin Immunol 2020;50:101428. [PMID: 33246736 DOI: 10.1016/j.smim.2020.101428] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
27 Morris DH, Petrova VN, Rossine FW, Parker E, Grenfell BT, Neher RA, Levin SA, Russell CA. Asynchrony between virus diversity and antibody selection limits influenza virus evolution. Elife 2020;9:e62105. [PMID: 33174838 DOI: 10.7554/eLife.62105] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
28 Carreño JM, McDonald JU, Hurst T, Rigsby P, Atkinson E, Charles L, Nachbagauer R, Behzadi MA, Strohmeier S, Coughlan L, Aydillo T, Brandenburg B, García-Sastre A, Kaszas K, Levine MZ, Manenti A, McDermott AB, Montomoli E, Muchene L, Narpala SR, Perera RAPM, Salisch NC, Valkenburg SA, Zhou F, Engelhardt OG, Krammer F. Development and Assessment of a Pooled Serum as Candidate Standard to Measure Influenza A Virus Group 1 Hemagglutinin Stalk-Reactive Antibodies. Vaccines (Basel) 2020;8:E666. [PMID: 33182279 DOI: 10.3390/vaccines8040666] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
29 Heida R, Bhide YC, Gasbarri M, Kocabiyik Ö, Stellacci F, Huckriede ALW, Hinrichs WLJ, Frijlink HW. Advances in the development of entry inhibitors for sialic-acid-targeting viruses. Drug Discov Today 2021;26:122-37. [PMID: 33099021 DOI: 10.1016/j.drudis.2020.10.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
30 Sun W, Luo T, Liu W, Li J. Progress in the Development of Universal Influenza Vaccines. Viruses 2020;12:E1033. [PMID: 32957468 DOI: 10.3390/v12091033] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
31 Du R, Cui Q, Rong L. Flu Universal Vaccines: New Tricks on an Old Virus. Virol Sin 2021;36:13-24. [PMID: 32870450 DOI: 10.1007/s12250-020-00283-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
32 van der Woude R, Turner HL, Tomris I, Bouwman KM, Ward AB, de Vries RP. Drivers of recombinant soluble influenza A virus hemagglutinin and neuraminidase expression in mammalian cells. Protein Sci 2020;29:1975-82. [PMID: 32710576 DOI: 10.1002/pro.3918] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
33 Madsen A, Cox RJ. Prospects and Challenges in the Development of Universal Influenza Vaccines. Vaccines (Basel) 2020;8:E361. [PMID: 32640619 DOI: 10.3390/vaccines8030361] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
34 Sato-Kaneko F, Yao S, Lao FS, Shpigelman J, Messer K, Pu M, Shukla NM, Cottam HB, Chan M, Chu PJ, Burkhart D, Schoener R, Matsutani T, Carson DA, Corr M, Hayashi T. A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity. Front Immunol 2020;11:1207. [PMID: 32636840 DOI: 10.3389/fimmu.2020.01207] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
35 Choi A, Ibañez LI, Strohmeier S, Krammer F, García-Sastre A, Schotsaert M. Non-sterilizing, Infection-Permissive Vaccination With Inactivated Influenza Virus Vaccine Reshapes Subsequent Virus Infection-Induced Protective Heterosubtypic Immunity From Cellular to Humoral Cross-Reactive Immune Responses. Front Immunol 2020;11:1166. [PMID: 32582220 DOI: 10.3389/fimmu.2020.01166] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
36 Shirvani E, Paldurai A, Varghese BP, Samal SK. Contributions of HA1 and HA2 Subunits of Highly Pathogenic Avian Influenza Virus in Induction of Neutralizing Antibodies and Protection in Chickens. Front Microbiol 2020;11:1085. [PMID: 32582071 DOI: 10.3389/fmicb.2020.01085] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
37 Crank MC, Mascola JR, Graham BS. Preparing for the Next Influenza Pandemic: The Development of a Universal Influenza Vaccine. J Infect Dis 2019;219:S107-9. [PMID: 30715413 DOI: 10.1093/infdis/jiz043] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
38 Morris DH, Petrova VN, Rossine FW, Parker E, Grenfell BT, Neher RA, Levin SA, Russell CA. Asynchrony between virus diversity and antibody selection limits influenza virus evolution.. [DOI: 10.1101/2020.04.27.064915] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Choi A, García-Sastre A, Schotsaert M. Host immune response-inspired development of the influenza vaccine. Ann Allergy Asthma Immunol 2020;125:28-35. [PMID: 32325117 DOI: 10.1016/j.anai.2020.04.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
40 Ostrowsky J, Arpey M, Moore K, Osterholm M, Friede M, Gordon J, Higgins D, Molto-Lopez J, Seals J, Bresee J. Tracking progress in universal influenza vaccine development. Curr Opin Virol 2020;40:28-36. [PMID: 32279026 DOI: 10.1016/j.coviro.2020.02.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
41 Wei CJ, Crank MC, Shiver J, Graham BS, Mascola JR, Nabel GJ. Next-generation influenza vaccines: opportunities and challenges. Nat Rev Drug Discov 2020;19:239-52. [PMID: 32060419 DOI: 10.1038/s41573-019-0056-x] [Cited by in Crossref: 106] [Cited by in F6Publishing: 111] [Article Influence: 53.0] [Reference Citation Analysis]
42 Wang J, Wiltse A, Zand MS. A Complex Dance: Measuring the Multidimensional Worlds of Influenza Virus Evolution and Anti-Influenza Immune Responses. Pathogens 2019;8:E238. [PMID: 31731815 DOI: 10.3390/pathogens8040238] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
43 Kharchenko EP. The Search for a Universal Influenza Vaccine: Possibilities and Limitations. Epidemiology and Vaccinal Prevention 2019;18:70-84. [DOI: 10.31631/2073-3046-2019-18-5-70-84] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Henry C, Palm AE, Utset HA, Huang M, Ho IY, Zheng NY, Fitzgerald T, Neu KE, Chen YQ, Krammer F, Treanor JJ, Sant AJ, Topham DJ, Wilson PC. Monoclonal Antibody Responses after Recombinant Hemagglutinin Vaccine versus Subunit Inactivated Influenza Virus Vaccine: a Comparative Study. J Virol 2019;93:e01150-19. [PMID: 31434733 DOI: 10.1128/JVI.01150-19] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
45 McMahon M, Asthagiri Arunkumar G, Liu WC, Stadlbauer D, Albrecht RA, Pavot V, Aramouni M, Lambe T, Gilbert SC, Krammer F. Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge. Front Immunol 2019;10:2005. [PMID: 31497029 DOI: 10.3389/fimmu.2019.02005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
46 Broecker F, Liu STH, Suntronwong N, Sun W, Bailey MJ, Nachbagauer R, Krammer F, Palese P. A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains. NPJ Vaccines 2019;4:31. [PMID: 31341648 DOI: 10.1038/s41541-019-0126-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
47 Reina J, Reina N. Universal influenza vaccination: Future prospects. Vacunas (English Edition) 2019;20:72-81. [DOI: 10.1016/j.vacune.2019.10.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Reina J, Reina N. Vacunación antigripal universal: perspectivas de futuro. Vacunas 2019;20:72-81. [DOI: 10.1016/j.vacun.2019.07.002] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
49 Sun W, Kirkpatrick E, Ermler M, Nachbagauer R, Broecker F, Krammer F, Palese P. Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach. J Virol 2019;93:e00333-19. [PMID: 30944178 DOI: 10.1128/JVI.00333-19] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 11.7] [Reference Citation Analysis]
50 [DOI: 10.1101/2020.02.24.963611] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]